Staphylococcal phages as agents of evolution and innovation: From gene flow to next-generation therapeutics
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Genetics and Molecular Biology
- Vol. 49 (suppl 1) , e20250131
Abstract
Staphylococcus species include both well-known pathogens and overlooked reservoirs of antimicrobial resistance. With rising resistance rates and limited treatment options, especially for methicillin-resistant strains, interest in alternative therapies has resurged. Among them, bacteriophages (phages) are promising biological agents due to their high specificity, low toxicity, ability to disrupt biofilms, and co-evolution with bacterial hosts. This review explores the biology, pan-genomics, diversity, and therapeutic relevance of staphylococcal phages. We revisit their historical discovery and re-emergence as tools against multidrug-resistant infections, highlighting morphological features, replication strategies, and recent taxonomic updates. Genomic analyses reveal distinct clusters of genome sizes, rare presence of resistance genes, and implications of transduction, bacterial defense systems, and phage-encoded anti-defense mechanisms. Preclinical studies show broad host range and synergistic activity with diverse antimicrobial agents, while engineered phage enzymes expand therapeutic possibilities. Clinical evidence, though limited, supports safety and efficacy in compassionate-use cases and early trials targeting Staphylococcus. Finally, we examine business models translating phage innovation into applied therapies, emphasizing regulatory, logistical, and financial challenges. In this broader context, phage technologies are not just alternatives to antibiotics-they represent an opportunity for innovation in global health. Their full potential depends on coordinated actions across science, industry, and policy.Keywords
Funding Information
- CNPq (408564/2023-7)
- CNPq (408678/2024-0)
- CNPq (E-26/201.071/2020)
- CNPq (APQ-03498-22)
- FAPERJ (408564/2023-7)
- FAPERJ (408678/2024-0)
- FAPERJ (E-26/201.071/2020)
- FAPERJ (APQ-03498-22)
- FAPEMIG (408564/2023-7)
- FAPEMIG (408678/2024-0)
- FAPEMIG (E-26/201.071/2020)
- FAPEMIG (APQ-03498-22)
This publication has 117 references indexed in Scilit:
- Chimeric Phage Lysins Act Synergistically with Lysostaphin To Kill Mastitis-Causing Staphylococcus aureus in Murine Mammary GlandsApplied and Environmental Microbiology, 2012
- Staphylococcus aureus Secretes Coagulase and von Willebrand Factor Binding Protein to Modify the Coagulation Cascade and Establish Host InfectionsJournal of Innate Immunity, 2012
- Phage treatment of human infectionsBacteriophage, 2011
- The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?Pharmaceutical Research, 2010
- Restriction–modification systems and bacteriophage invasion: Who wins?Journal of Theoretical Biology, 2010
- Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milkInternational Journal of Food Microbiology, 2010
- Phage therapy experience at the Eliava InstituteMedecine Et Maladies Infectieuses, 2008
- On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. RouxResearch in Microbiology, 2007
- Bacteriophage TherapyAnnual Review of Microbiology, 2001
- Further Investigations on the Nature of Ultra-Microscopic Viruses and their CultivationEpidemiology and Infection, 1936